| Beide Seiten der vorigen Revision
Vorhergehende Überarbeitung
|
Letzte Überarbeitung
Beide Seiten der Revision
|
croton_lechleri_muell._arg [2015/06/13 11:38]
127.0.0.1 Externe Bearbeitung |
croton_lechleri_muell._arg [2017/10/09 20:21]
andreas |
| |
| "Crofelemer inhibited the cystic fibrosis transmembrane regulator (CFTR) Cl− channel with maximum inhibition of ~60% and an IC50 ~7 μM... Crofelemer was also found to strongly inhibit the intestinal calcium-activated Cl− channel TMEM16A by a voltage-independent inhibition mechanism with maximum inhibition >90% and IC50 ~6.5 μM. The dual inhibitory action of crofelemer on two structurally unrelated prosecretory intestinal Cl− channels may account for its intestinal antisecretory activity." \\ | "Crofelemer inhibited the cystic fibrosis transmembrane regulator (CFTR) Cl− channel with maximum inhibition of ~60% and an IC50 ~7 μM... Crofelemer was also found to strongly inhibit the intestinal calcium-activated Cl− channel TMEM16A by a voltage-independent inhibition mechanism with maximum inhibition >90% and IC50 ~6.5 μM. The dual inhibitory action of crofelemer on two structurally unrelated prosecretory intestinal Cl− channels may account for its intestinal antisecretory activity." \\ |
| [Crofelemer, an Antisecretory Antidiarrheal Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal Chloride Channels. Tradtrantip, L.; Namkung, W.; Verkman, A. S., Molecular Pharmacology, Vol.77(1), 2010, 69–78] [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802429/]] | [Crofelemer, an Antisecretory Antidiarrheal Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal Chloride Channels. Tradtrantip, L.; Namkung, W.; Verkman, A. S., Molecular Pharmacology, Vol.77(1), 2010, 69-78] [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802429/]] |
| |
| " In studies in diarrheal illness associated with primarily a secretory component, such as cholera, travelers’ diarrhea and acute infectious diarrhea, crofelemer has shown improvements in stool consistency and duration of symptoms. Less clear, but interesting, results have been observed in other diarrheal diseases associated with a mixed pathology, including diarrhea in patients with HIV and diarrhea-predominant irritable bowel syndrome." \\ | "In studies in diarrheal illness associated with primarily a secretory component, such as cholera, travelers’ diarrhea and acute infectious diarrhea, crofelemer has shown improvements in stool consistency and duration of symptoms. Less clear, but interesting, results have been observed in other diarrheal diseases associated with a mixed pathology, including diarrhea in patients with HIV and diarrhea-predominant irritable bowel syndrome." \\ |
| [Crofelemer for the treatment of secretory diarrhea. Cottreau, Jessica, et al., Expert Review of Gastroenterology & Hepatology, Vol.6(1), 2012, 17-23] | [Crofelemer for the treatment of secretory diarrhea. Cottreau, Jessica, et al., Expert Review of Gastroenterology & Hepatology, Vol.6(1), 2012, 17-23] |
| |
| | "As an incense material, it is particularly attractive for coloring mixtures, whereas its scent is neither particularly strong nor characteristic." \\ |
| | [Niebler, Johannes, "Incense Materials" in: Buettner, Andrea, ed. Springer Handbook of Odor. Springer, 2017, 73] |
